Curasight's technology
More than 50% of all cancer patients would at some time receive external radiation therapy. However, traditional radiation therapy also irradiates healthy tissue, leading to serious side effects. Curasight's new type of radiation therapy solves this problem. Curasight's technology build on the principle called Targeted Radionuclide Therapy.
With Curasight's technology, the patient is not irradiated from the outside, but instead a substance injected into a blood vessel automatically seeks out and binds to the cancer. From there, the substance sends out radiation with a range of just one millimetre, irradiating the cancer while minimising irradiation of healthy tissue.
By using imaging, it is possible to know for sure that the therapy reaches the cancer. The exact same substance that is used for therapy, just modified, and now used for imaging, can exactly predict where the therapy will work. This is called the Theranostic (Therapy – Diagnostics) principle. By starting with imaging, only patients with a clear tumour uptake will proceed to targeted radionuclide therapy. This is personalised, tailored cancer therapy.
uTRACE®
Curasights technology to find, visualise and predict whether a cancer is aggressive and if so, how it should be treated.
uTREAT®
Curasights new type of personalised and tailored targeted radiation therapy.
uPAR Theranostics
Curasight's novel and innovative Theranostics platform for improved cancer diagnose and treatment.
Nuclear medicine in brief
Nuclear medicine is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear medicine imaging, in a sense, is radiology done inside out" or "endoradiology" because it records radiation emitting from within the body rather than radiation that is generated by external sources like X-rays. In addition, nuclear medicine scans differ from radiology, as the emphasis is not on imaging anatomy, but on the function. For such reason, it is called a physiological imaging modality. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) scans are the two most common imaging modalities in nuclear medicine.
